Uroprotectant
Mesna
Brand names: Uromitexan
Adult dose
Dose: Per oncology protocol — typically 60–160% of cyclophosphamide/ifosfamide dose, given IV at 0, 4, 8h
Route: IV/PO
Frequency: per protocol
Clinical pearls
- Prevention of haemorrhagic cystitis with cyclophosphamide/ifosfamide
- Always co-prescribed with these agents at oncology doses
Contraindications
- Hypersensitivity to thiol compounds
Side effects
- Hypersensitivity (incl. severe rash, anaphylaxis)
- Headache
- GI upset
Monitoring
- Urinalysis
Reference: BNF; SmPC; https://bnf.nice.org.uk/drugs/mesna/. Verify against your local formulary and the latest BNF before prescribing.
Related
Curated clinical cross-links plus same-class fallbacks.
Pathways
- Major Haemorrhage / Massive Transfusion · BCSH; RCOA; RCEM; RCS — BCSH Guidelines
- Anaemia Investigation · BSH / NICE
- Splenomegaly Workup · BSH; BMJ Best Practice
- Deep Vein Thrombosis Diagnosis and Treatment · NICE CG144 / NICE NG158
- Sickle Cell Crisis · BSH 2021 / BCSH
- Neutropenic Sepsis · NICE CG151 2012 / ESMO